Core summary of product characteristics for plasma-derived fibrin sealant/haemostatic products

Current effective version

PDF iconRevision 1 - Adopted guideline

Reference numberEMA/CHMP/BPWP/598816/2010 Rev. 1
Published25/06/2015
Effective from01/01/2016
KeywordsFibrin sealant, haemostatics, human fibrinogen, factor XIII, antifibrinolytics, aprotinin, tranexamic acid, human thrombin, sealant, otologic, rhinologic, ophthalmic and vertebral surgery, cerebro-spinal fluid, dura mater, glueing, neurosurgery, treatment of bleeding, vascular surgery, gastrointestinal anastomoses
DescriptionThis document describes the information to be included in the summary of product characteristics for plasma-derived fibrin sealant/haemostatic products.


Document history

Revision 1

Current version

PDF iconAdopted guideline


PDF iconOverview of comments


PDF iconConcept paper


PDF iconDraft guideline

In operation: 01/01/2016–present


Published: 25/06/2015


Published: 28/05/2014


Published: 27/09/2011

First version PDF iconAdopted guideline In operation: 01/01/2005–01/01/2016


Related content


How useful was this page?

Add your rating